A phase II study of gemcitabine, carboplatin and PS-341 (NSC-681239) [bortezomib] in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

Trial Profile

A phase II study of gemcitabine, carboplatin and PS-341 (NSC-681239) [bortezomib] in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 23 Jul 2012 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.
    • 02 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top